OAKVILLE, Ontario, June 3, 2019 /PRNewswire/ -- Cardiol Therapeutics
Inc. (TSX: CRDL; OTCQX: CRTPF) ("Cardiol" or the "Company"),
a leader in the research and commercial development of
pharmaceutical CBD and targeted therapies for inflammatory
diseases, announces that David
Elsley, President and CEO of Cardiol, will present live at
VirtualInvestorConferences.com on June
4th.
DATE: Tuesday, June
4th
TIME: 9:30
AM EST
LINK: https://tinyurl.com/June4CannabisVIC
This will be a live, interactive online event where investors
are invited to ask the company questions in real-time. If attendees
are not able to join the event live on the day of the conference,
an archived webcast will also be made available after the
event.
It is recommended that investors pre-register and run the online
system check to expedite participation and receive event
updates.
Learn more about the event at
www.VirtualInvestorConferences.com.
About Virtual Investor Conferences
Virtual Investor Conferences is the leading proprietary investor
conference series that provides an interactive forum for publicly
traded companies to meet and present
directly with investors. A real-time solution for investor
engagement, Virtual Investor Conferences is part of OTC Market
Group's suite of investor relations services specifically designed
for more efficient Investor Access. Replicating the look and
feel of on-site investor conferences, Virtual Investor Conferences
combine leading-edge conferencing and investor communications
capabilities with a comprehensive global investor audience
network.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. is a leader in the research and
commercial development of pharmaceutical CBD products and targeted
therapies for inflammatory disease. The Company is leveraging its
expertise in pharmaceutical CBD to develop ultra-pure CBD products
for commercialization in the billion dollar market for medicinal
cannabinoids in Canada, with a
view to expanding into Latin
America and Europe, and
utilizing nanotechnologies designed to deliver cannabinoids and
other anti-inflammatory drugs for the treatment of heart failure.
Heart failure is a leading cause of death and hospitalization, with
associated healthcare costs exceeding $30 billion annually in the U.S. alone. For
further information about Cardiol, please visit the Company's
website at www.cardiolrx.com.
View original
content:http://www.prnewswire.com/news-releases/cardiol-therapeutics-to-webcast-live-at-virtualinvestorconferencescom-on-june-4th-300860950.html
SOURCE VirtualInvestorConferences.com